Lista de obras - Simon Harrison - Dominio Público Uruguay

A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients

artículo científico publicado en 2014

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

artículo científico publicado en 2012

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

artículo científico publicado en 2011

A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease.

artículo científico publicado en 2013

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2014

A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

artículo científico publicado en 2012

Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection

artículo científico publicado en 2015

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies

artículo científico publicado en 2016

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

artículo científico publicado en 2017

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

artículo científico publicado en 2010

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

artículo científico publicado en 2012

Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.

artículo científico publicado en 2010

Caregivers' information needs and their 'experiences of care' during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors

artículo científico publicado en 2016

Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. ⬇️

artículo científico publicado en 2015

Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection

artículo científico

Clinical studies of histone deacetylase inhibitors.

artículo científico publicado en 2009

Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma".

artículo científico publicado en 2015

Complete remission of localised gastric plasmacytomas following definitive radiotherapy

artículo científico publicado en 2012

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

artículo científico publicado en 2011

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

artículo científico publicado en 2013

Emergence of central nervous system myeloma in the era of novel agents

artículo científico publicado en 2011

Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma

artículo científico publicado en 2016

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

artículo científico publicado en 2005

Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.

artículo científico publicado en 2008

Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy

artículo científico publicado en 2016

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

artículo científico publicado en 2010

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia

scientific article published on 05 April 2019

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

artículo científico publicado en 2019

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

artículo científico publicado en 2010

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

artículo científico publicado en 2015

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide

artículo científico publicado en 2013

Images in haematology. Erythrophagocytosis

scientific article published on 01 April 2001

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

artículo científico publicado en 2014

Immunotherapy in multiple myeloma--possibility or probability?

artículo científico publicado en 2005

Immunotherapy of multiple myeloma: the start of a long and tortuous journey

artículo científico publicado en 2006

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis

artículo científico publicado en 2016

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

artículo científico publicado en 2017

Intracranial involvement by multiple myeloma.

artículo científico publicado en 2015

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.

artículo científico publicado en 2014

Lessons Learned From an Unusual Presentation of CD3+, CD56− T-Cell Large Granular Lymphocyte Leukemia

artículo científico publicado en 2010

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

scientific article published on 05 March 2014

Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.

scientific article published on 27 June 2013

Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in Australia

artículo científico publicado en 2013

M(yeloma)IXing up T maintenance ⬇️

artículo científico publicado el 5 de enero de 2012

Management of heparin allergy during pregnancy with danaparoid

artículo científico publicado en 2001

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

artículo científico publicado en 2015

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

artículo científico publicado en 2016

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

artículo científico publicado en 2010

Multiple myeloma of the spine

artículo científico publicado en 2017

Myeloma and pregnancy: strange bedfellows?

artículo científico publicado en 2013

Myeloma of the central nervous system - an ongoing conundrum!

artículo científico publicado en 2016

Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss

artículo científico publicado en 2015

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

artículo científico publicado en 2014

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

artículo científico publicado en 2010

Outcome of the Stryker® Trident 'All-Poly' constraint acetabular insert: a district general hospital experience

artículo científico publicado en 2015

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

artículo científico publicado en 2010

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

artículo científico publicado en 2012

Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study

artículo científico publicado en 2013

Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections

artículo científico publicado en 2012

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

artículo científico publicado en 2016

Physical Activity Preferences for People Living With Multiple Myeloma: A Qualitative Study

artículo científico publicado en 2016

Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature.

artículo científico

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

scientific article published on 02 June 2014

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

artículo científico publicado en 2017

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

artículo científico publicado en 2009

Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization

artículo científico publicado en 2015

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

artículo científico publicado en 2011

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital

artículo científico publicado en 2014

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy

artículo científico publicado en 2015

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

artículo científico publicado en 2016

Systematic review of quality improvement interventions directed at cancer specialists

artículo científico publicado en 2013

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

artículo científico publicado en 2016

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

artículo científico publicado en 2004

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

artículo científico publicado en 2015

The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.

artículo científico

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period

artículo científico publicado en 2017

The development of novel immunotherapeutic approaches in multiple myeloma.

artículo científico publicado en 2008

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

artículo científico publicado en 2010

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers

artículo científico publicado en 2017

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

artículo científico publicado en 2014

The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

artículo científico publicado en 2008

The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

artículo científico

To validate: is it so simple?

artículo científico publicado en 2011

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

artículo científico publicado en 2017

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

artículo científico

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

artículo científico publicado en 2015

Update and new approaches in the treatment of Castleman disease

artículo científico publicado en 2016

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

artículo científico publicado en 2017

Lista de obras de Simon Harrison

A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients

A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

A messenger at the door: cytomegalovirus retinitis in myeloma patients with progressive disease.

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.

Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.

Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.

Caregivers' information needs and their 'experiences of care' during treatment are associated with elevated anxiety and depression: a cross-sectional study of the caregivers of renal cancer survivors

Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma. ⬇️

Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection

Clinical studies of histone deacetylase inhibitors.

Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma".

Complete remission of localised gastric plasmacytomas following definitive radiotherapy

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

Emergence of central nervous system myeloma in the era of novel agents

Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma

Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.

Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide

Images in haematology. Erythrophagocytosis

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

Immunotherapy in multiple myeloma--possibility or probability?

Immunotherapy of multiple myeloma: the start of a long and tortuous journey

Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

Intracranial involvement by multiple myeloma.

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.

Lessons Learned From an Unusual Presentation of CD3+, CD56− T-Cell Large Granular Lymphocyte Leukemia

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy

Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.

Low uptake of upfront autologous transplantation for myeloma in a jurisdiction with universal health care coverage: a population-based patterns of care study in Australia

M(yeloma)IXing up T maintenance ⬇️

Management of heparin allergy during pregnancy with danaparoid

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Multiple myeloma of the spine

Myeloma and pregnancy: strange bedfellows?

Myeloma of the central nervous system - an ongoing conundrum!

Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

Outcome of the Stryker® Trident 'All-Poly' constraint acetabular insert: a district general hospital experience

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study

Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections

Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

Physical Activity Preferences for People Living With Multiple Myeloma: A Qualitative Study

Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature.

Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital

Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.

Systematic review of quality improvement interventions directed at cancer specialists

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period

The development of novel immunotherapeutic approaches in multiple myeloma.

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers